Race and ethnicity in the era of emerging pharmacogenomics

Journal of Clinical Pharmacology

Volumn 46, Issue 4, 2006, Pages 405-407

  Harty, Lea ^a   Johnson, Keith ^a   Power, Aidan ^a  

^a PFIZER INC   (United States)

Author keywords

Ethnicity; Genetics; Pharmacogenomics; Race

Indexed keywords

ABACAVIR; APOLIPOPROTEIN E4; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HLA ANTIBODY; HYDRALAZINE PLUS ISOSORBIDE DINITRATE;

ALZHEIMER DISEASE; CLINICAL TRIAL; CULTURAL FACTOR; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG RESPONSE; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; GENE CLUSTER; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE UTILIZATION; HEALTH STATUS; HEART FAILURE; HUMAN; INCOME; PHARMACOGENOMICS; RACE DIFFERENCE; SHORT SURVEY;

BIOMEDICAL RESEARCH; CONTINENTAL POPULATION GROUPS; CULTURAL CHARACTERISTICS; ETHNIC GROUPS; HUMAN GENOME PROJECT; HUMANS; PHARMACOGENETICS;

EID: 33644984585     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005286028     Document Type: Short Survey

References (29)

1. Branca MA. BiDil raises questions about race as a marker. Nat Rev Drug Disc. 2005;4:615-616.
2. FDA News. FDA approves BiDil heart failure drug for black patients. June 23, 2005. Food and Drug Administration Web site. Available at: http://www.fda.gov/bbs/topics/NEWS/2005/NEW01190.html.
3. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
4. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547-1552.
5. Researchers seek to determine whether genetic variations may affect patients' response to new heart failure therapy; data presented at Heart Failure Society of America Annual Meeting [press release]. Lexington, Mass: NitroMed. Available at: http://www.nitromed.com/09_21a_05.asp.
6. Barbujani G, Goldstein D. Africans and Asians abroad: genetic diversity in Europe. Annu Rev Genomics Hum Genet. 2004;5:119-150.
7. King M-C, Motulsky A. Mapping human history. Science. 2002;298:2342-2343.
8. The Royal Society. Personalized Medicines: Hopes and Realities. London, United Kingdom: The Royal Society; 2005.
9. Groeneveld PW, Laufer SB, Garber AM. Technology diffusion, hospital variation, and racial disparities among elderly Medicare beneficiaries 1989-2000. Med Care. 2005;43:320-329.
10. Cooper RS. Social inequality, ethnicity and cardiovascular disease. Int J Epidemiol. 2001;30(suppl 1):S48-S52.
11. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003;348:1170-1175.
12. Risch N, Burchard E, Ziv E, Tang H. Categorization of humans in biomedical research: genes, race and disease. Genome Biol. 2002;3:comment 2007.1-comment 2007.12.
13. Schwartz R. Racial profiling in medical research. N Engl J Med. 2001;344:1392-1393.
14. Fullilove MT. Comment: abandoning "race" as a variable in public health research - an idea whose time has come. Am J Public Health. 1998;88:1297-1298.
15. Rivara FP, Finberg L. Use of the terms race and ethnicity. Arch Pediatr Adolesc Med. 2001;155:119.
16. Jones CP. Invited commentary: "race," racism, and the practice of epidemiology. Am J Epidemiol. 2001;154:299-304.
17. Riener AP, Ziv E, Lind DL, et al. Population structure, admixture, and aging-related phenotypes in African American Adults: the Cardiovascular Health Study. Am J Hum Genet. 2005;76:463-477.
18. Cooper RS, Kaufman JS, Ward R. Race and genomics. N Engl J Med. 2003;348:1166-1170.
19. Kaufman JS, Cooper RS. Considerations for use of racial/ethnic classification in etiologic research. Am J Epidemiol. 2001;154:291-298.
20. Kahn J. Misreading race and genomics after BiDil. Nat Genet. 2005;37:655-656.
21. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349-1356.
22. Ioannidis JPA, Ntzani EE, Trikalinos TA. "Racial" differences in genetic effects for complex diseases. Nat Genet. 2004;36:1312-1318.
23. Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol. 2003;43:943-967.
24. Wood AJJ. Racial differences in the response to drugs - pointers to genetic differences. N Engl J Med. 2001;344:1393-1396.
25. Dominick KL, Bosworth HB, Hsieh JB, Moser BK. Racial differences in analgesic/anti-inflammatory medication use and perceptions of efficacy. J Natl Med Assoc. 2004;96:928-932.
26. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variation in HLA-B region with hypersensitivity to abacavir in some, hut not all, populations. Pharmacogenomics. 2004:5:203-211.
27. Wilson JF, Weale ME, Smith AC, et al. Population genetic structure of variable drug response. Nat Genet. 2001;29:265-269.
28. The International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
29. Goldstein DB, Cavalleri GL. Understanding human diversity. Nature. 2005;437:1241-1242.